<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kappos, Ludwig</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results of DECIDE: DAC HYP Superior to IFN-β-1a for RRMS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">This article describes the results of the phase 3, randomized, double-blind, double-dummy, active-controlled Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis trial [DECIDE; NCT01064401] establishing the superiority of the humanized monoclonal antibody, daclizumab high-yield process (DAC HYP), to interferon beta-1a (IFN-β-1a) in the treatment of relapsing-remitting multiple sclerosis (RRMS).</style></abstract><number><style face="normal" font="default" size="100%">29</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>